 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 5 | 1/1 | 返回列表 |
| 查看: 2088 | 回復: 4 | |||
[求助]
JEADV和JEADV Clinical Practice是啥關系？ 已有1人參與
|
|
投論文后給了如下回復： I am afraid I cannot offer high enough priority to your paper for us to accept it for publication in the Journal of the European Academy of Dermatology and Venereology. As you can appreciate, the Journal receives many more manuscripts than can be published and so there has to be some degree of prioritisation. I realise that this decision will be disappointing to you. However, I think your paper is a well-suited candidate for publication in the JEADV Clinical Practice, the companion title of Journal of the European Academy of Dermatology and Venereology, with a primary focus on clinically oriented and educational content. I would like to offer you the opportunity to transfer your paper and the associated reviews automatically to the JEADV Clinical Practice. JEADV Clinical Practice: JEADV Clinical Practice is a broad scope Open Access journal featuring cutting-edge clinical and educational content, hands-on information relevant to managing the dermatologist’s and venereologist’s office and the acquisition of clinical and surgical skills. Particular attention will be given to research articles, imaging diagnosis, case reports and articles featuring innovative techniques and procedures with high quality images and videos. 然后想知道JEADV和JEADV Clinical Practice是啥關系，這個“the companion title”是啥意思��？ JEADV Clinical Practice這個搜不到啊…… |
回復此樓» 猜你喜歡
347求調(diào)劑
已經(jīng)有7人回復
-
080500材料科學與工程
已經(jīng)有10人回復
-
材料類考研調(diào)劑
已經(jīng)有8人回復
-
化學專業(yè)調(diào)劑
已經(jīng)有3人回復
-
274環(huán)境工程求調(diào)劑
已經(jīng)有5人回復
-
本子寫完了，給DS兄弟看了，得了92分
已經(jīng)有10人回復
-
考研282分求調(diào)劑，接受跨專業(yè)
已經(jīng)有6人回復
-
304求調(diào)劑
已經(jīng)有3人回復
-
求調(diào)劑，學校研究所都可以，材料與化工267分
已經(jīng)有3人回復
-
一志愿清華深研院材料專碩294分，專業(yè)課111分，本科中南大學材料，有六級，有工作經(jīng)驗
已經(jīng)有3人回復
nono2009
超級版主 (文學泰斗)
No gains, no pains.
-
專家經(jīng)驗: +21105 - SEPI: 10
- 應助: 28684 (院士)
- 貴賓: 513.911
- 金幣: 2555220
- 散金: 27828
- 紅花: 2147
- 沙發(fā): 66666
- 帖子: 1602255
- 在線: 65200.9小時
- 蟲號: 827383
- 注冊: 2009-08-13
- 性別: GG
- 專業(yè): 工程熱物理與能源利用
- 管轄: 科研家籌備委員會
2樓2022-06-04 19:36:17
3樓2022-06-08 08:09:09
nono2009
超級版主 (文學泰斗)
No gains, no pains.
-
專家經(jīng)驗: +21105 - SEPI: 10
- 應助: 28684 (院士)
- 貴賓: 513.911
- 金幣: 2555220
- 散金: 27828
- 紅花: 2147
- 沙發(fā): 66666
- 帖子: 1602255
- 在線: 65200.9小時
- 蟲號: 827383
- 注冊: 2009-08-13
- 性別: GG
- 專業(yè): 工程熱物理與能源利用
- 管轄: 科研家籌備委員會
4樓2022-06-08 08:10:09
hym0411
木蟲 (正式寫手)
- 應助: 16 (小學生)
- 金幣: 3135.6
- 散金: 50
- 紅花: 5
- 帖子: 760
- 在線: 221.6小時
- 蟲號: 1403571
- 注冊: 2011-09-15
- 性別: MM
- 專業(yè): 免疫學
5樓2023-12-29 19:52:32
相關版塊跳轉(zhuǎn)
我要訂閱樓主 casper123 的主題更新
| 5 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 歡迎211本科同學，過A區(qū)國家線，A區(qū)非偏遠一本，交叉學科課題組 +10 | lisimayy 2026-03-04 | 18/900 |
|
|---|---|---|---|---|
|
|
[考研] 302材料工程求調(diào)劑 +7 | Doleres 2026-03-01 | 8/400 |
|
|
[考研] 中國科學技術大學材料與化工281求調(diào)劑，有科研和獲獎經(jīng)歷 +11 | wsxw 2026-03-02 | 12/600 |
|
|
|
[考研] 267調(diào)劑求助 +5 | 聰少OZ 2026-03-04 | 5/250 |
|
|
|
[考研] 0703化學求調(diào)劑，總分320分，一志愿中南民族大學 +3 | 19286712440 2026-03-04 | 3/150 |
|
|
|
[考研] 0703化學求調(diào)劑 +3 | 將未有期 2026-03-04 | 3/150 |
|
|
|
[考研] 292求調(diào)劑 +9 | yhk_819 2026-02-28 | 9/450 |
|
|
|
[考研] 312求調(diào)劑 +8 | 醋精華了一下發(fā)?/a> 2026-03-03 | 10/500 |
|
|
|
[考研] 347分電子信息專碩求調(diào)劑 +3 | 咕嘟咕嘟1 2026-03-03 | 3/150 |
|
|
|
[考博] 26申博 求博導 +3 | 愛讀書的小帥 2026-02-28 | 5/250 |
|
|
|
[考研] 環(huán)境調(diào)劑 +8 | chenhanheng 2026-03-02 | 8/400 |
|
|
|
[考研] 290求調(diào)劑 +9 | ErMiao1020 2026-03-02 | 9/450 |
|
|
|
[考研] 化工專碩348，一志愿985求調(diào)劑 +8 | 弗格個 2026-02-28 | 11/550 |
|
|
|
[考研] 化學0703求調(diào)劑 學碩 理/工科均可 總分279 +3 | 1一11 2026-03-03 | 5/250 |
|
|
|
[考研] 課題組接收材料類調(diào)劑研究生 +6 | gaoxiaoniuma 2026-02-28 | 9/450 |
|
|
|
[考研] 307求調(diào)劑 +6 | wyyyqx 2026-03-01 | 6/300 |
|
|
|
[考研] 290分材料工程085601求調(diào)劑 數(shù)二英一 +8 | llx0610 2026-03-02 | 9/450 |
|
|
|
[考博] 誠招農(nóng)業(yè)博士 +3 | 心欣向榮 2026-02-28 | 3/150 |
|
|
|
[考研] 化工專碩342，一志愿大連理工大學，求調(diào)劑 +6 | kyf化工 2026-02-28 | 7/350 |
|
|
|
[考研] 化工299分求調(diào)劑 一志愿985落榜 +5 | 嘻嘻(*^ω^*) 2026-03-01 | 5/250 |
|